Cargando…
CCND1 mutations increase protein stability and promote ibrutinib resistance in mantle cell lymphoma
Mantle cell lymphoma (MCL) is characterized by the t(11;14) translocation, which leads to deregulated expression of the cell cycle regulatory protein cyclin D1 (CCND1). Genomic studies of MCL have also identified recurrent mutations in the coding region of CCND1. However, the functional consequence...
Autores principales: | Mohanty, Atish, Sandoval, Natalie, Das, Manasi, Pillai, Raju, Chen, Lu, Chen, Robert W., Amin, Hesham M., Wang, Michael, Marcucci, Guido, Weisenburger, Dennis D., Rosen, Steven T., Pham, Lan V., Ngo, Vu N. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5341999/ https://www.ncbi.nlm.nih.gov/pubmed/27713153 http://dx.doi.org/10.18632/oncotarget.12434 |
Ejemplares similares
-
Cryptococcal meningoencephalitis in patients with mantle cell lymphoma on ibrutinib
por: Sun, Kai, et al.
Publicado: (2018) -
Targeting glutaminase is therapeutically effective in ibrutinib-resistant mantle cell lymphoma
por: Li, Lingzhi, et al.
Publicado: (2022) -
A case of new‐onset cardiomyopathy and ventricular tachycardia in a patient receiving ibrutinib for relapsed mantle cell lymphoma
por: Wallace, Natalie, et al.
Publicado: (2016) -
Dose-finding study of ibrutinib and venetoclax in relapsed or refractory mantle cell lymphoma
por: Portell, Craig A., et al.
Publicado: (2022) -
Ibrutinib in Relapsed or Refractory Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia
por: Peterson, Derek, et al.
Publicado: (2014)